Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | TYK2 | P29597 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15551280 | 0.84 | NUDT1 (0.40) | BACE1NUDT1KMT2ACNR1CNR2 | |
| SCHEMBL17556142 | 0.80 | BACE1 (0.41) | BACE1NUDT1KMT2ATLR8 | |
| SCHEMBL16657417 | 0.78 | NUDT1 (0.41) | BACE1NUDT1KMT2A | |
| SCHEMBL9979854 | 0.76 | BACE1 (0.54) | BACE1NUDT1KMT2AJAK2JAK1 | |
| SCHEMBL9974597 | 0.75 | KMT2A (0.43) | BACE1KMT2AKDM4E | |
| SCHEMBL16818436 | 0.75 | BRD4 (0.50) | KMT2AKDM4EHTT | |
| SCHEMBL16657416 | 0.74 | SMN1; SMN2 (0.39) | BACE1NUDT1KMT2AKDM4EPTGER4 | |
| SCHEMBL18053798 | 0.74 | MAPT (0.32) | JAK2JAK1TYK2JAK3CNR1 | |
| SCHEMBL18056688 | 0.72 | GRM2 (0.33) | — | |
| SCHEMBL15908544 | 0.71 | SMN1; SMN2 (0.45) | KMT2AJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251377-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-01 | — | — | US | claimed |
| US-9896459-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-20 | — | — | US | disclosed |
| US-9896459-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-20 | — | — | US | disclosed |
| US-9896459-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-20 | — | — | US | disclosed |
| EP-2909195-B1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2909195-B1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-06-14 | — | — | EP | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| EP-2651936-B1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-02-22 | — | — | EP | disclosed |
| US-9051317-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-09 | — | — | US | disclosed |
| US-9051317-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-09 | — | — | US | disclosed |
| WO-2014060411-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060411-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2014-04-24 | — | — | WO | disclosed |
| EP-2651936-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Janssen R&D Ireland (IE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267556-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267556-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267556-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080450-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080450-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251377-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, CCNI, ZC3HAV1 | BACE1 4218/4885NUDT1 310/4885KMT2A 1619/4885 |
| US-20130267556-A1 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, CCNI, ZC3HAV1 | BACE1 4218/4885NUDT1 310/4885KMT2A 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.